SCHEMBL4247679

SCHEMBL4247679

COCc1nc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2)nc1C(O)=S

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.57
SLC2A1 P11166 1/20 0.41
LMNA P02545 2/20 0.38
KDM4E B2RXH2 2/20 0.38
GAA P10253 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTGS2 P35354 1/20 0.37
PTGDR2 Q9Y5Y4 5/20 0.36
CDH1 P12830 1/20 0.35
APC P25054 1/20 0.35
CTNNB1 P35222 1/20 0.35
TCF7L2 Q9NQB0 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
KMO O15229 1/20 0.34
PGK1 P00558 1/20 0.34
CASP1 P29466 1/20 0.34
HTT P42858 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4681021 0.86 CNR1 (0.57) CNR1SLC2A1LMNAKDM4EGAA
SCHEMBL4243036 0.85 CNR1 (0.48) CNR1SLC2A1PTGDR2
SCHEMBL4600547 0.84 CNR1 (0.69) CNR1SLC2A1
SCHEMBL4247678 0.83 CNR1 (0.57) CNR1SLC2A1KDM4EL3MBTL1PTGS2
SCHEMBL4680862 0.82 CNR1 (0.59) CNR1LMNAKDM4EL3MBTL1PTGS2
SCHEMBL4600541 0.81 CNR1 (0.65) CNR1GAAPTGDR2TDP1HSD17B10
SCHEMBL4245861 0.79 CNR1 (0.41) CNR1SLC2A1LMNAPTGS2TDP1
SCHEMBL4676636 0.75 CNR1 (0.50) CNR1SLC2A1KDM4EGAAPTGDR2
SCHEMBL4243035 0.72 CNR1 (0.48) CNR1PTGDR2
SCHEMBL4680852 0.71 CNR1 (0.44) CNR1L3MBTL1PTGDR2CDH1APC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156616-A1 THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2009-06-18 US claimed
EP-1910304-A2 THERAPEUTIC AGENTS AstraZeneca AB (SE) 2008-04-16 EP claimed
WO-2007010222-A2 THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2007-01-25 WO claimed
US-20090156616-A1 THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2009-06-18 US disclosed
EP-1910304-A2 THERAPEUTIC AGENTS AstraZeneca AB (SE) 2008-04-16 EP disclosed
WO-2007010222-A2 THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156616-A1 THERAPEUTIC AGENTS NLN, BDNF, GAP43 CNR1 173/4885SLC2A1 807/4885LMNA 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.